Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

HYPERBARIC BUPIVACAINE FOR SPINAL ANALGESIA SOUTH AFRICAN MEDICAL JOURNAL Holloway, A. M., BROCKUTNE, J. G., Downing, J. W. 1982; 61 (9): 314-316

Abstract

Sixty-one patients (ASA classification I-III) were studied in an open non-comparative trial to assess the efficacy of hyperbaric bupivacaine for spinal anaesthesia. In 59 patients the quality of analgesic block was good, while 2 required supplementary analgesia and sedation. Four patients became hypotensive, this requiring correction by fluid volume replacement. Hyperbaric bupivacaine, with a mean duration of action of 6 1/2 hours, has proved satisfactory in our anaesthetic practice.

View details for Web of Science ID A1982ND15200021

View details for PubMedID 7036379